• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.

作者信息

Aguiar Pedro, Perry Luke A, Lopes Gilberto L

机构信息

Oncology & Hematology Department, Clinical Oncology Sector, Federal University of São Paulo, Brazil.

Monash School of Medicine, Faculty of Medicine, Nursing & Health Sciences, Melbourne, Australia.

出版信息

Lung Cancer Manag. 2016 Nov;5(3):119-122. doi: 10.2217/lmt-2016-0016. Epub 2016 Nov 3.

DOI:10.2217/lmt-2016-0016
PMID:30643555
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6322585/
Abstract
摘要

相似文献

1
Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.根据程序性死亡受体配体1（PD-L1）表达情况，免疫检查点抑制剂在非小细胞肺癌（NSCLC）中的成本效益。
Lung Cancer Manag. 2016 Nov;5(3):119-122. doi: 10.2217/lmt-2016-0016. Epub 2016 Nov 3.
2
Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review.免疫检查点抑制剂治疗非小细胞肺癌的成本效益：系统评价。
PLoS One. 2020 Sep 2;15(9):e0238536. doi: 10.1371/journal.pone.0238536. eCollection 2020.
3
What impacts the cost-effectiveness of PD-L1 testing in non-small cell lung cancer?PD-L1 检测在非小细胞肺癌中的成本效益有哪些影响因素？
Lung Cancer. 2019 Jun;132:152-153. doi: 10.1016/j.lungcan.2019.03.011. Epub 2019 Mar 11.
4
The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.PD-L1 检测对 NSCLC 二线治疗中免疫检查点抑制剂的成本效益和经济影响的影响。
Ann Oncol. 2017 Sep 1;28(9):2256-2263. doi: 10.1093/annonc/mdx305.
5
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC.IDO-1、PD-L1 和 MEK 的三重阻断作为 NSCLC 的潜在治疗策略。
J Transl Med. 2022 Nov 22;20(1):541. doi: 10.1186/s12967-022-03730-y.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.综合基因组分析、肿瘤突变负担和 PD-L1 表达的整合，以鉴定非小细胞肺癌免疫治疗的新型生物标志物。
Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2.
8
Effect of PD-L1 Expression for the PD-1/L1 Inhibitors on Non-small Cell Lung Cancer: A Meta-analysis Based on Randomised Controlled Trials.基于随机对照试验的 PD-L1 表达对 PD-1/L1 抑制剂治疗非小细胞肺癌效果的 Meta 分析。
Clin Oncol (R Coll Radiol). 2023 Oct;35(10):640-651. doi: 10.1016/j.clon.2023.07.012. Epub 2023 Jul 31.
9
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].[晚期非小细胞肺癌且PD-L1高表达患者对免疫检查点抑制剂单药治疗或联合化疗反应的评估]
Zhongguo Fei Ai Za Zhi. 2021 Mar 20;24(3):161-166. doi: 10.3779/j.issn.1009-3419.2021.103.02.
10
Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.在中国，对于高 PD-L1 表达的非小细胞肺癌患者，确定最佳的 PD-1/PD-L1 抑制剂作为一线治疗药物。
Cancer Med. 2021 Sep;10(18):6344-6353. doi: 10.1002/cam4.4191. Epub 2021 Aug 12.

引用本文的文献

1
Implementing performance-based risk-sharing agreements in non-small cell lung cancer immunotherapy: a real-world data case study.在非小细胞肺癌免疫治疗中实施基于绩效的风险分担协议：一项真实世界数据案例研究
Health Econ Rev. 2025 Jun 9;15(1):49. doi: 10.1186/s13561-025-00646-3.
2
Foreword: message from the Editor.前言：编辑寄语
Lung Cancer Manag. 2016 Dec;5(4):155-157. doi: 10.2217/lmt-2017-0002. Epub 2017 Jun 5.
3
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.奥希替尼一线治疗表皮生长因子受体突变阳性晚期非小细胞肺癌的成本效果分析。
JAMA Oncol. 2018 Aug 1;4(8):1080-1084. doi: 10.1001/jamaoncol.2018.1395.
4
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.用于晚期非小细胞肺癌的免疫检查点抑制剂：新治疗靶点的新兴测序技术
ESMO Open. 2017 Jul 29;2(3):e000200. doi: 10.1136/esmoopen-2017-000200. eCollection 2017.

本文引用的文献

1
The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis.程序性死亡配体1（PD-L1）表达作为晚期非小细胞肺癌预测生物标志物的作用：一项网状荟萃分析。
Immunotherapy. 2016;8(4):479-88. doi: 10.2217/imt-2015-0002.
2
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis.PD-L1表达与接受抗PD-1/PD-L1药物治疗的非小细胞肺癌患者预后的相关性：一项荟萃分析。
Crit Rev Oncol Hematol. 2016 May;101:75-85. doi: 10.1016/j.critrevonc.2016.03.007. Epub 2016 Mar 6.
3
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis.PD-L1表达作为非小细胞肺癌患者的预测性生物标志物：一项汇总分析。
Oncotarget. 2016 Apr 12;7(15):19738-47. doi: 10.18632/oncotarget.7582.
4
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.帕博利珠单抗对比多西他赛用于治疗后 PD-L1 阳性的、晚期非小细胞肺癌（KEYNOTE-010）：一项随机对照试验。
Lancet. 2016 Apr 9;387(10027):1540-1550. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
5
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.纳武利尤单抗对比多西他赛治疗晚期非鳞状非小细胞肺癌
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
6
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.纳武单抗与多西他赛治疗晚期鳞状细胞非小细胞肺癌的疗效比较
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
7
Pembrolizumab for the treatment of non-small-cell lung cancer.帕博利珠单抗治疗非小细胞肺癌。
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
8
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.欧洲非小细胞肺癌（NSCLC）患者一线铂类化疗的治疗结果和资源利用情况：FRAME前瞻性观察研究
Lung Cancer. 2015 May;88(2):215-22. doi: 10.1016/j.lungcan.2015.02.011. Epub 2015 Feb 21.
9
Development and economic trends in cancer therapeutic drugs: a 5-year update 2010-2014.癌症治疗药物的发展与经济趋势：2010 - 2014年五年更新
Br J Cancer. 2015 Mar 17;112(6):1037-41. doi: 10.1038/bjc.2015.56.
10
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.分子通路：下一代免疫疗法——抑制程序性死亡配体 1 和程序性死亡受体 1。
Clin Cancer Res. 2012 Dec 15;18(24):6580-7. doi: 10.1158/1078-0432.CCR-12-1362. Epub 2012 Oct 19.